Cargando…

A Bispecific Inhibitor of the EGFR/ADAM17 Axis Decreases Cell Proliferation and Migration of EGFR-Dependent Cancer Cells

Dysregulated epidermal growth factor receptor (EGFR) is an oncogenic driver of many human cancers, promoting aberrant cell proliferation, migration, and survival. Pharmacological targeting of EGFR is often challenged by acquired mechanisms of resistance. Ligand-dependent mechanisms in EGFR wild-type...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soto-Gamez, Abel, Chen, Deng, Nabuurs, Anke G.E., Quax, Wim J., Demaria, Marco, Boersma, Ykelien L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072247/ https://www.ncbi.nlm.nih.gov/pubmed/32050662 http://dx.doi.org/10.3390/cancers12020411

Ejemplares similares

The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology
por: Stolarczyk, Marta, et al.
Publicado: (2018)

Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands
por: Sahin, Umut, et al.
Publicado: (2004)

ADAM metalloproteases and EGFR signalling
por: Gee, Julia MW, et al.
Publicado: (2003)

ADAM17-mediated EGFR ligand shedding directs macrophage-promoted cancer cell invasion
por: Gnosa, Sebastian P., et al.
Publicado: (2022)

High-Throughput Screening in Protein Engineering: Recent Advances and Future Perspectives
por: Wójcik, Magdalena, et al.
Publicado: (2015)

ADAM10 and ADAM17 regulate EGFR, c-Met and TNF RI signalling in liver regeneration and fibrosis
por: Zbodakova, Olga, et al.
Publicado: (2021)

Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency
por: Fu, Wenyan, et al.
Publicado: (2023)

Polarization of ADAM17‐driven EGFR signalling in electric field‐guided collective migration of epidermal sheets
por: Jia, Naixin, et al.
Publicado: (2020)

Rosmarinic acid inhibits proliferation and migration, promotes apoptosis and enhances cisplatin sensitivity of melanoma cells through inhibiting ADAM17/EGFR/AKT/GSK3β axis
por: Huang, Lin, et al.
Publicado: (2021)

Engineering the specificity of Streptococcus pyogenes sortase A by loop grafting
por: Wójcik, Magdalena, et al.
Publicado: (2020)

eIg-based bispecific T-cell engagers targeting EGFR: Format matters
por: Kühl, Lennart, et al.
Publicado: (2023)

Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand–dependent terminal keratinocyte differentiation
por: Franzke, Claus-Werner, et al.
Publicado: (2012)

Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation
por: Franzke, Claus-Werner, et al.
Publicado: (2012)

FoxM1 drives ADAM17/EGFR activation loop to promote mesenchymal transition in glioblastoma
por: Zhang, Chunli, et al.
Publicado: (2018)

An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations
por: Jin, Junyeong, et al.
Publicado: (2018)

ADAM17/EGFR axis promotes transglutaminase-dependent skin barrier formation through phospholipase C γ1 and protein kinase C pathways
por: Wolf , Cristina, et al.
Publicado: (2016)

Corrigendum: ADAM17/EGFR axis promotes transglutaminase-dependent skin barrier formation through phospholipase C γ1 and protein kinase C pathways
por: Wolf, Cristina, et al.
Publicado: (2017)

Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing
por: Li, Li, et al.
Publicado: (2020)

Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
por: Lum, Lawrence G., et al.
Publicado: (2020)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

IL-17R–EGFR axis links wound healing to tumorigenesis in Lrig1(+) stem cells
por: Chen, Xing, et al.
Publicado: (2019)

The iRhom2/ADAM17 Axis Attenuates Bacterial Uptake by Phagocytes in a Cell Autonomous Manner
por: Seifert, Anke, et al.
Publicado: (2020)

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
por: Eggermont, Carolien, et al.
Publicado: (2022)

Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation
por: Kuwahara, Atsushi, et al.
Publicado: (2020)

Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells
por: Siney, Elodie J., et al.
Publicado: (2016)

HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells
por: Chou, Chia-Wei, et al.
Publicado: (2011)

Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI–Mediated Anticancer Activity in NSCLC
por: Yang, Zheng, et al.
Publicado: (2019)

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity
por: Castoldi, R, et al.
Publicado: (2013)

The Gut-Brain Axis in Autism Spectrum Disorder: A Focus on the Metalloproteases ADAM10 and ADAM17
por: Zheng, Yuanpeng, et al.
Publicado: (2020)

An IL-17-EGFR-TRAF4 axis contributes to the alleviation of lung inflammation in severe influenza
por: Dutta, Avijit, et al.
Publicado: (2023)

Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1
por: Mohan, Nishant, et al.
Publicado: (2022)

ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via EGFR/ERK signaling pathway
por: Xu, Jinming, et al.
Publicado: (2023)

Dihydroartemisinin-Transferrin Adducts Enhance TRAIL-Induced Apoptosis in Triple-Negative Breast Cancer in a P53-Independent and ROS-Dependent Manner
por: Zhou, Xinyu, et al.
Publicado: (2022)

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
por: Ploeg, Emily Maria, et al.
Publicado: (2023)

Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
por: Grugan, Katharine D., et al.
Publicado: (2016)

ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy
por: Harwood, Seandean Lykke, et al.
Publicado: (2017)

A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity
por: Boustany, Leila M., et al.
Publicado: (2022)

EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells
por: Melo, Vinicio, et al.
Publicado: (2023)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
por: Oh, Felix, et al.
Publicado: (2020)

Novel EGFR-bispecific recombinant immunotoxin based on cucurmosin shows potent anti-tumor efficiency in vitro
por: Zhang, Caiyun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gmq8gq3frnfarvpc1pt81p3nms